@entity319 Gene Polymorphisms and Response to Anti- @entity7 Therapy in Age-Related XXXX .

@entity1 @entity70579 @entity7 @entity319 @entity3193 @entity1020 @entity68087
PURPOSE: A previously published study demonstrated a pharmacogenetic association between the minor alleles of 2 @entity319 single nucleotide polymorphisms (SNPs) and greater improvement in visual acuity (VA) to treatment with ranibizumab, an @entity7 ( @entity7 ) drug, in @entity1 with neovascular @entity1020 ( @entity1020 ). We evaluated whether this association was replicated among @entity1 who participated in the Comparison of @entity1020 Treatments Trials (CATT) or the Alternative Treatments to Inhibit @entity7 in @entity1 with Age-Related @entity3193 (IVAN) trial. DESIGN: Cohort studies within randomized clinical trials. @entity1 : Eight hundred thirty-five @entity1 participating in CATT and 512 @entity1 participating in IVAN. METHODS: Each @entity1 was genotyped for the SNPs @entity68087 and @entity70579 in the @entity319 gene. MAIN OUTCOMES MEASURES: Mean change in VA from baseline to 1 year after initiation of treatment with ranibizumab or bevacizumab. Differences in VA response between the @entity1 group homozygous for the minor allele of each SNP and the other genotype groups were evaluated with analysis of variance. Differences in VA response by the number of minor alleles present for either SNP or both combined were evaluated with tests of linear trend. Analyses were conducted separately for CATT and IVAN @entity1 and with both the studies combined. RESULTS: No statistically significant difference in mean change in VA was identified between genotypes of either SNP (P >=  0.05). Furthermore, a stepwise analysis failed to show a significant interaction for either SNP based on the number of minor alleles present. The lack of association was similar in both the CATT and IVAN cohorts and whether the analysis combined @entity1 treated with either ranibizumab or bevacizumab or when restricted to @entity1 treated with ranibizumab only. CONCLUSIONS: The CATT and IVAN data do not support a pharmacogenetic association between the 2  @entity319 SNPs, @entity68087 and @entity70579 , and change in VA in response to anti- @entity7 therapy in @entity1 with @entity1020 .
